{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"22","upperLimit":"50","value":"35"},{"groupId":"OG001","lowerLimit":"24","upperLimit":"51","value":"37"}]}],"title":"After 3 cycles"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"33","upperLimit":"62","value":"47"},{"groupId":"OG001","lowerLimit":"34","upperLimit":"62","value":"48"}]}],"title":"After 6 cycles"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"42","upperLimit":"71","value":"57"},{"groupId":"OG001","lowerLimit":"43","upperLimit":"71","value":"58"}]}],"title":"After 9 cycles"}],"denoms":[{"counts":[{"groupId":"OG000","value":"49"},{"groupId":"OG001","value":"52"}],"units":"Participants"}],"description":"Response was assessed by the investigator using International Myeloma Working Group (IMWG) Criteria. CR is defined as negative immunofixation on the serum and urine and; disappearance of any soft tissue plasmacytomas and; \\< 5% plasma cells in bone marrow. VGPR is defined as Serum and urine M-protein detectable by immunofixation but not on electrophoresis or 90% or greater reduction in serum M-protein plus urine M-protein level \\< 100 mg per 24 hours.","dispersionType":"95% Confidence Interval","groups":[{"description":"In phase 2, ixazomib 4.0 mg fixed dose, capsules, orally, once, on Days 1, 8 and 15; plus dexamethasone 40 mg, tablets, orally, once on Days 1, 8, 15 and 22; and lenalidomide 25 mg, capsules, orally, once on Days 1 through 21 of a 28-day cycle for up to 12 cycles. Cycle 13 and beyond, single agent ixazomib 4.0 mg fixed dose, capsules, orally, once on Days 1, 8 and 15 of a 28-day cycle until disease progression or unacceptable toxicity.","id":"OG000","title":"Phase 2: Ixazomib 4.0 mg + Lenalidomide + Dexamethasone"},{"description":"In phase 2, ixazomib 4.0 mg fixed dose, capsules, orally, once, on Days 1, 8 and 15; plus dexamethasone 40 mg, tablets, orally, once, on Days 1, 8, 15 and 22; and lenalidomide 25 mg, capsules, orally, once, on Days 1 through 21 of a 28-day cycle for up to 12 cycles. Cycle 13 and beyond, single agent ixazomib 4.0 mg fixed dose, capsules, orally, once on Days 1, 8 and 15 of a 28-day cycle until disease progression or unacceptable toxicity. Includes 3 participants who received 2.23 mg/m\\^2 in Phase 1.","id":"OG001","title":"Phase 2: Ixazomib 4.0 mg/2.23 + Lenalidomide + Dexamethasone"}],"paramType":"NUMBER","populationDescription":"The response-evaluable population was defined as all patients who received at least one dose of ixazomib, had measurable disease at baseline, and at least one post-baseline disease assessment.","reportingStatus":"POSTED","timeFrame":"After Cycles 3, 6 and 9 (Up to 787 days)","title":"Phase 2: Percentage of Participants With Complete Response (CR) and Very Good Partial Response (VGPR)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}